Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer
Dana E. Rathkopf(Memorial Sloan Kettering Cancer Center), Andrew J. Armstrong(Duke University), Manish R. Patel(Sarah Cannon), Jessica E. Hawley(Columbia University Irving Medical Center), Michael Pourdehnad(Bristol-Myers Squibb (Germany)), Raju Kandimalla(Baylor University Medical Center), Jing Han(National Center for Toxicological Research), Hamid Emamekhoo(University of Wisconsin Carbone Cancer Center), Karie Runcie(Columbia University Irving Medical Center), Vinod Arora(Bristol-Myers Squibb (Sweden)), Vivek Narayan(Hospital of the University of Pennsylvania), Drew Rasco(Texas Oncology), Atish D. Choudhury(Dana-Farber Cancer Institute), Jiwen Wu(Bristol-Myers Squibb (Sweden)), Alan Wells(University of Pittsburgh), S. Srinivas(Unknown), Zachery R. Reichert(National Cancer Institute), Chun‐Yu Liu(Division of Materials Science and Engineering), Minh Nguyen(Bristol-Myers Squibb (Sweden)), Ana Aparicio(The University of Texas MD Anderson Cancer Center), S Suryawanshi(Bristol-Myers Squibb (Sweden)), Nehal J. Lakhani(South Texas Accelerated Research Therapeutics)
Cited by 66
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k